Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Heath

Showing results (211-220 of 248) with videos related to

Pageof 25
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2018
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid TumorsDaniel D Von Hoff, Drew W Rasco, Elisabeth I Heath, et al.
The Lancet. Oncology|May 15, 2021
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trialEvan Y Yu, Daniel P Petrylak, Peter H O'Donnell, et al.
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
JCO Precision Oncology|February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumMaria I Carlo, Veda N Giri, Channing J Paller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2025
Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic SubtypesJustin Hwang, Pornlada Likasitwatanakul, Sachin Kumar Deshmukh, et al.
Cancer Research Communications|May 6, 2024
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human MalignanciesCarly D Miller, John R Lozada, Nicholas A Zorko, et al.
Clinical Genitourinary Cancer|June 8, 2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumChanning J Paller, Emmanuel S Antonarakis, Tomasz M Beer, et al.
Prostate Cancer and Prostatic Diseases|March 1, 2020
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registryOliver Sartor, Andrew J Armstrong, Chiledum Ahaghotu, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
Inhibition of PIM kinase in tumor associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapyAmber N Clements, Andrea L Casillas, Caitlyn E Flores, et al.
Pageof 25

Showing results (211-220 of 248) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2018
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid TumorsDaniel D Von Hoff, Drew W Rasco, Elisabeth I Heath, et al.
The Lancet. Oncology|May 15, 2021
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trialEvan Y Yu, Daniel P Petrylak, Peter H O'Donnell, et al.
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
JCO Precision Oncology|February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumMaria I Carlo, Veda N Giri, Channing J Paller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2025
Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic SubtypesJustin Hwang, Pornlada Likasitwatanakul, Sachin Kumar Deshmukh, et al.
Cancer Research Communications|May 6, 2024
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human MalignanciesCarly D Miller, John R Lozada, Nicholas A Zorko, et al.
Clinical Genitourinary Cancer|June 8, 2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumChanning J Paller, Emmanuel S Antonarakis, Tomasz M Beer, et al.
Prostate Cancer and Prostatic Diseases|March 1, 2020
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registryOliver Sartor, Andrew J Armstrong, Chiledum Ahaghotu, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
Inhibition of PIM kinase in tumor associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapyAmber N Clements, Andrea L Casillas, Caitlyn E Flores, et al.
Pageof 25